Table 2. Predicted AMR of gonorrhea positive nucleic acid amplification specimens from Nunavut, 2018–2019*.
| Resistance | MICs, mg/L | No. specimens with AMR/no. predicted (%) |
|||
|---|---|---|---|---|---|
| Qikiqtaaluk | Kivalliq | Kitikmeot | Total | ||
| Decreased susceptibility to cephalosporins |
≥0.125 |
0/591 (0) |
1/350 (0.3) |
0/35 (0) |
1/976 (0.1) |
| Intermediate cephalosporin MICs |
0.032–0.063 |
303/591 (51.3) |
49/350 (14.0) |
8/35 (22.9) |
360/976 (36.9) |
| Ciprofloxacin resistant |
≥1 |
298/591 (50.4) |
50/351 (14.2) |
7/35 (20.0) |
355/977 (36.3) |
| Azithromycin resistant |
≥2 |
66/583 (11.3) |
2/350 (0.6) |
0/35 (0) |
68/968 (7.0) |
| *Denominators indicate predicted number of samples with susceptibility for the given antimicrobial. Not all samples were tested for antimicrobial susceptibilities and not all the samples that were tested gave conclusive results. AMR, antimicrobial resistance. | |||||